Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (629)	8/12/2001 6:52:11 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 717

Thanks Peter and WilderElisimo. I got excited about PCYC back in 1997 or 1998 due to Peter's comments and made money investing in the company from time to time. Now, my concerns are the same as WilderElisimo.

To: keokalani'nui who wrote (629)	12/15/2001 6:13:44 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 717

from Wilder....... Any enterprising MD, though, ought to be able to get an audience with one of the investigators using xcytrin in the many other open label trials. That could produce some very interesting info. from Feuerstein's balanced and timely report..... J.P. Morgan analyst Corey Davis walked away from the meeting more confident than ever of Xcytrin's chances, based on hallway chats with some of the drug's investigators. "Our investigator conversations were extremely positive and very suggestive -- yet we need to emphasize, far from conclusive -- of a survival benefit for Xcytrin," he wrote in a Nov. 9 research note that reiterated his buy rating on the stock. Davis' firm has performed underwriting for Pharmacyclics. Message 16645739 So much for chatting up those who should know best. ;-(